Approach to the triple negative breast cancer in new drugs area

International Journal of Hematology-Oncology and Stem Cell Research

Volumn 10, Issue 2, 2016, Pages 115-119

  Mirzania, Mehrzad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

gpNMB; PARP inhibitors; PI3K AKT mTOR pathway; Src family kinase; Triple negative breast cancers

Indexed keywords

ANDROGEN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GLEMBATUMUMAB VEDOTIN; GONADORELIN RECEPTOR; INIPARIB; IPATASERTIB; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TEMOZOLOMIDE; VELIPARIB; VORINOSTAT; ZOPTARELIN DOXORUBICIN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DNA DAMAGE; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; EPIGENETICS; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84963613088     PISSN: 17351243     EISSN: 20082207     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134(7): e48-72.
2. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011; 103:470.
3. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013; 137(1):307-14.
4. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67.
5. Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007; 8(8): R157.
6. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12 (5): R68.
7. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19(2):264-71.
8. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81.
9. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363:1938.
10. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006; 24(13):2019-27.
11. Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56.
12. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015; 33(1):13-21.
13. Byrski T, Gronwald J, Huzarski T, et al. Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers - results of treatment. Hered Cancer Clin Pract. 2012; 10 (Suppl 3): A3.
14. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012; 30: 2615-23.
15. Tutt A, Robson M, Garber JE, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-44.
16. Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single-agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011; 17(21): 6905-13.
17. Rose AA, Grosset AA, Dong Z, et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res. 2010; 16: 2147-56.
18. Yardley DA, Weaver R, Melisko ME, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol. 2015; 33:1609-19.
19. Seitz S, Buchholz S, Schally AV, et al. (2014) Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer. 14: 847.
20. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999; 13(22): 2905-2927.
21. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121:2750-2767.